Business Context and Reporting Period
This Form 8-K filing by Ligand Pharmaceuticals Incorporated (LGND) reports the final voting results from the Company's 2025 Annual Meeting of Stockholders, held on June 6, 2025. The report was filed on June 9, 2025.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The filing details the outcomes of three proposals submitted to stockholders:
- Proposal 1 (Election of Directors): All eight nominees were elected to the Board of Directors for terms expiring at the 2026 annual meeting.
- Jason M. Aryeh: 13,595,137 votes For; 3,224,879 votes Withheld.
- Todd C. Davis: 16,393,716 votes For; 426,300 votes Withheld.
- Nancy R. Gray, Ph.D.: 16,470,033 votes For; 349,983 votes Withheld.
- Jason Haas: 16,621,292 votes For; 198,724 votes Withheld.
- John W. Kozarich, Ph.D.: 15,684,962 votes For; 1,135,054 votes Withheld.
- John L. LaMattina, Ph.D.: 15,961,637 votes For; 858,379 votes Withheld.
- Stephen L. Sabba, M.D.: 15,789,883 votes For; 1,030,133 votes Withheld.
- Martine Zimmermann, Pharm.D.: 16,666,655 votes For; 153,361 votes Withheld.
- Proposal 2 (Ratification of Auditors): The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
- Votes For: 17,274,429
- Votes Against: 906,847
- Abstentions: 2,322
- Proposal 3 (Executive Compensation): The non-binding advisory resolution regarding the compensation of named executive officers was approved.
- Votes For: 15,576,200
- Votes Against: 1,183,843
- Abstentions: 59,973
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, outlook, or discussions of risks and contingencies. It is strictly a disclosure of shareholder voting outcomes.
Key Facts for Investor Verification
- Verify the composition of the Board of Directors for the 2025-2026 term based on the election results.
- Confirm the appointment of Ernst & Young LLP as the auditor for the fiscal year ending December 31, 2025.
- Note the level of shareholder support for executive compensation (approximately 93% of votes cast were in favor).
- Review the number of broker non-votes (1,363,582) which were recorded for all director elections and the executive compensation proposal.